Brief: Pulmatrix Announces First Patient Dosed In Phase 2B Study Of Pur1900 For Treatment Of Allergic Bronchopulmonary Aspergillosis In Subjects With Asthma
06/02/2023 16:14
Feb 6 (Reuters) - Pulmatrix Inc PULM.O :
* PULMATRIX ANNOUNCES FIRST PATIENT DOSED IN PHASE 2B STUDY
OF
PUR1900 FOR TREATMENT OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
(ABPA) IN SUBJECTS WITH ASTHMA
Source text for Eikon: ID:nPn3bPRFra
Further company coverage: PULM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulmatrix
See all newsBrief: Pulmatrix Announces Second Quarter 2026 Financial Results And Progress On Merger
Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM